๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Aurangabad
Clinical trial register · India

Clinical Trials in Aurangabad, 2026

Every study on the ClinicalTrials.gov registry that lists a site in India and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 1132 matching records held by the registry are in this view. Synced 26 Sep 2026, 03:16 UTC
1132
Studies in scope
all four open statuses
613
Recruiting now
open to new participants
221
Lead sponsors
across recruiting studies
Top sites
New Delhi 335 Mumbai 261 Hyderabad 238 Bangalore 199 Pune 189
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Eli Lilly and Company5 Boehringer Ingelheim2 ImmunityBio, Inc.1 Intra-Cellular Therapies, Inc.1 Otsuka Pharmaceutical Development & Commercialization, Inc.1
Site location
New Delhi335 Mumbai261 Hyderabad238 Bangalore199 Pune189
All 275 locations
Target enrolment
to

Trials with a site in Aurangabad

23 of 1132 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Indian sites
Start
Recruiting
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT07759245Pulmonary Disease, Chronic Obstructive
DrugBrenipatide
Eli Lilly and Company
Phase 2
606
Ahmedabad, Allahฤbฤd, Aurangabad, Bangalore, Lucknow, New Delhi, Noida, Pune
2026-08-07
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
460
Aurangabad, Pune, Rishikesh, Kolkata, Delhi
2026-05-27
Recruiting
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
NCT07361497Non-small Cell Lung Cancer (NSCLC)
DrugsPumitamig·Durvalumab
Bristol-Myers Squibb
Phase 3
850
Eluru, Goraj, Pลซlakkลd, Aurangabad, Mumbai, Nagpur, Dwarka, New Delhi
2026-03-16
Recruiting
A Study of Brenipatide in Adult Participants With Schizophrenia
NCT07410507Schizophrenia
DrugBrenipatide
Eli Lilly and Company
Phase 2
450
Aurangabad, Bhopal, Dharwad, Karjat, Kolhฤpur, Lucknow, Navi Mumbai, Pune
2026-02-10
Recruiting
Real-world Evaluation of the Effectiveness of Immunoglobulin-Histamine Complex, IHC (Histoglob) in Chronic Urticaria
NCT07680413Chronic Urticaria
Bharat Serums and Vaccines Limited
Observational
600
Ahmedabad, Vadodara, Faridabad, Gurgaon, Bangalore, Mysore, Aurangabad, Nanded
2025-12-31
Recruiting
A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
NCT07286175Bipolar Disorder
DrugBrenipatide
Eli Lilly and Company
Phase 2
400
Aurangabad, Belgavi, Bhopal, Chhatrapati Sambhajinagar, Dehradun, Dharwad, Lucknow, Mysore
2025-11-24
Recruiting
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
NCT07219173Asthma
DrugBrenipatide
Eli Lilly and Company
Phase 2
531
Aurangabad, Bangalore, Bhubaneswar, Dwฤrka, Kanpur, New Delhi, Pune, Raipur
2025-10-22
Recruiting
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
NCT07000357Cardiovascular Disease
DrugAZD0780
AstraZeneca
Phase 3
15,100
Ahmedabad, Aurangabad, Bangalore, Belagavi, Bikaner, Calicut, Chennai, Coimbatore
2025-06-04
Recruiting
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370Heart Failure
DrugsVicadrostat·Empagliflozin
Boehringer Ingelheim
Phase 3
4,200
Aurangabad, Bangalore, Bikaner, Chennai, Kochi, Kolkata, Nashik, New Delhi
2025-05-20
Recruiting
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598Carcinoma, Non-Small-Cell Lung
DrugsOlomorasib·Durvalumab·Pembrolizumab
Eli Lilly and Company
Phase 3
700
Ahmedabad, Aurangabad, Chennai, Mumbai, Namakkal, Patna, Pune, Thalassery
2025-03-27
Recruiting
Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced Lymphoma
NCT06755450Relapsed Advanced Lymphomas
Aurigene Discovery Technologies Limited
Phase 1
40
Vadodara, Jhajjar, Bangalore, Aurangabad, Nagpur, Pune, Satara, Thane
2025-01-15
Recruiting
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787Alzheimer Disease
DrugKarXT
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
406
Aurangabad, Nagpur, Chandigarh, Ajmer, Hyderabad, Kolkata, Varanasi
2024-09-26
Recruiting
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288Heart Failure
DrugsVicadrostat·Empagliflozin
Boehringer Ingelheim
Phase 3
6,712
Aurangabad, Bangalore, Bengaluru, Bikaner, Chennai, Gurgaon, Guwahati, Kochi
2024-06-17
Recruiting
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
NCT06372964Bipolar Depression
DrugLumateperone
Intra-Cellular Therapies, Inc.
Phase 3
384
Ahmedabad, Aurangabad, Nashik, Varanasi
2024-05-14
Active, closed
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869Atrial Fibrillation
DrugsMilvexian·Apixaban
Janssen Research & Development, LLC
Phase 3
20,284
Aligarh, Amritsar, Aurangabad, Bangalore, Belagavi, Bengaluru, Bikaner, Chennai
2023-04-11
Recruiting
Erythropoietin for Neonatal Encephalopathy in LMIC (EMBRACE Trial)
NCT05395195Encephalopathy, Erythropoietin, Newborn Asphyxia
Imperial College London
Phase 3
504
Aurangabad, Bangalore, Chennai, Hubli, Mumbai
2022-12-31
Active, closed
LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT05321420Idiopathic Pulmonary Fibrosis
DrugsDeupirfenidone·Pirfenidone
PureTech
Phase 2
240
Vadodara, Bengaluru, Aurangabad, Nagpur, Hyderabad, Kanpur, Kolkata, Belagฤve
2022-07-22
Active, closed
A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.
NCT05878691Advanced Solid Tumor, Lymphoma
DrugsAtezolizumab·Pembrolizumab
Glenmark Specialty S.A.
Phase 1
320
Vijayawada, Visakhapatnam, Gurgaon, Bangalore, Bengaluru, Kannur, Aurangabad, Mumbai
2022-06-28
Active, closed
Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
NCT05248646Immunoglobulin A Nephropathy
DrugSibeprenlimab
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
530
Ahmedabad, Nadiฤd, Bengaluru, Manipal, Kozhikode, Thiruvananthapuram, Aurangabad, Pune
2022-03-15
Active, closed
Assessment of Safety and Effectiveness of NovoSorbยฎ BTM in Severe Burns
NCT04090424Burns
PolyNovo Biomaterials Pty Ltd.
Not applicable
150
Aurangabad, Mumbai, Coimbatore
2021-09-21
By invitation
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
NCT04957719Acute Myocardial Infarction
Viatris Innovation GmbH
Phase 3
25,000
Ahmedabad, Aligarh, Aurangabad, Bangalore, Bathinda, Belagavi, Bhubaneswar, Bikaner
2021-08-14
Recruiting
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
NCT04613596Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
DrugsAdagrasib·Pembrolizumab
Mirati Therapeutics Inc.
Phase 2/3
626
Ahemdabad, Ahmedabad, Aurangabad, Bangalore, Belagavi, Howrah, Hyderabad, Jaipur
2020-12-02
Active, closed
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
NCT02138734Non-muscle Invasive Bladder Cancer
ImmunityBio, Inc.
Phase 1/2
369
Visakhapatnam, Adyฤr, Ahmedabad, Aurangabad, Nagpur, Pune, Mumbai, New Delhi
2014-07-21
Rows per page Showing 1–23 of 23
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Indian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-india/city/aurangabad

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in India and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 1,132 studies in total at the last sync on 26 Sep 2026, 03:16 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 23 of those studies with a site in Aurangabad.

How many clinical trials are recruiting in Aurangabad?

16 of the 23 studies on this page are recruiting new participants as of the 26 Sep 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 6 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Aurangabad), 23 studies
PhaseStudiesRecruitingShare
Phase 312952.2%
Phase 25421.7%
Phase 1218.7%
Not applicable104.3%
Observational114.3%
Phase 1/2104.3%
Phase 2/3114.3%

Most active sponsors

Lead sponsors with the most studies (Aurangabad)
Lead sponsorStudiesRecruiting
Eli Lilly and Company55
Boehringer Ingelheim22
AstraZeneca11
Aurigene Discovery Technologies Limited11
Bharat Serums and Vaccines Limited11
Bristol-Myers Squibb11
Glenmark Specialty S.A.10
ImmunityBio, Inc.10
Imperial College London11
Intra-Cellular Therapies, Inc.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.